Discussing edaravone with the ALS patient

an ethical framework from a U.S. perspective

Crystal Jing Jing Yeo, Zachary Simmons

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The recent approval of edaravone by the United States Food and Drug Administration has generated a mix of hope tempered by reality. The costs of the drug, both monetarily and with regard to intensity of treatment, are high. The benefits, while modest, will be viewed through a very different lens by individuals depending on their goals of care. By virtue of our training and experience, physicians are ideally suited to understand and explain new treatments to our patients. As healthcare providers with a fiduciary responsibility to our patients, we must make sure they are fully informed about both the costs and benefits of non-curative therapies such as edaravone, and be prepared to discuss these in the context of their goals of care and potential impact on quality of life. Respect for our patients’ autonomy is critical when discussing these issues, but we should always be guided by the ethical principles of beneficence and non-maleficence.

Original languageEnglish (US)
Pages (from-to)167-172
Number of pages6
JournalAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration
Volume19
Issue number3-4
DOIs
StatePublished - Apr 3 2018

Fingerprint

Patient Care Planning
Hope
Beneficence
Drug Costs
United States Food and Drug Administration
Health Personnel
Lenses
Cost-Benefit Analysis
Therapeutics
Quality of Life
Physicians
phenylmethylpyrazolone

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology

Cite this

@article{df517b485f614e0596100063c0bf8885,
title = "Discussing edaravone with the ALS patient: an ethical framework from a U.S. perspective",
abstract = "The recent approval of edaravone by the United States Food and Drug Administration has generated a mix of hope tempered by reality. The costs of the drug, both monetarily and with regard to intensity of treatment, are high. The benefits, while modest, will be viewed through a very different lens by individuals depending on their goals of care. By virtue of our training and experience, physicians are ideally suited to understand and explain new treatments to our patients. As healthcare providers with a fiduciary responsibility to our patients, we must make sure they are fully informed about both the costs and benefits of non-curative therapies such as edaravone, and be prepared to discuss these in the context of their goals of care and potential impact on quality of life. Respect for our patients’ autonomy is critical when discussing these issues, but we should always be guided by the ethical principles of beneficence and non-maleficence.",
author = "Yeo, {Crystal Jing Jing} and Zachary Simmons",
year = "2018",
month = "4",
day = "3",
doi = "10.1080/21678421.2018.1425455",
language = "English (US)",
volume = "19",
pages = "167--172",
journal = "Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration",
issn = "2167-8421",
publisher = "Informa Healthcare",
number = "3-4",

}

Discussing edaravone with the ALS patient : an ethical framework from a U.S. perspective. / Yeo, Crystal Jing Jing; Simmons, Zachary.

In: Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, Vol. 19, No. 3-4, 03.04.2018, p. 167-172.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Discussing edaravone with the ALS patient

T2 - an ethical framework from a U.S. perspective

AU - Yeo, Crystal Jing Jing

AU - Simmons, Zachary

PY - 2018/4/3

Y1 - 2018/4/3

N2 - The recent approval of edaravone by the United States Food and Drug Administration has generated a mix of hope tempered by reality. The costs of the drug, both monetarily and with regard to intensity of treatment, are high. The benefits, while modest, will be viewed through a very different lens by individuals depending on their goals of care. By virtue of our training and experience, physicians are ideally suited to understand and explain new treatments to our patients. As healthcare providers with a fiduciary responsibility to our patients, we must make sure they are fully informed about both the costs and benefits of non-curative therapies such as edaravone, and be prepared to discuss these in the context of their goals of care and potential impact on quality of life. Respect for our patients’ autonomy is critical when discussing these issues, but we should always be guided by the ethical principles of beneficence and non-maleficence.

AB - The recent approval of edaravone by the United States Food and Drug Administration has generated a mix of hope tempered by reality. The costs of the drug, both monetarily and with regard to intensity of treatment, are high. The benefits, while modest, will be viewed through a very different lens by individuals depending on their goals of care. By virtue of our training and experience, physicians are ideally suited to understand and explain new treatments to our patients. As healthcare providers with a fiduciary responsibility to our patients, we must make sure they are fully informed about both the costs and benefits of non-curative therapies such as edaravone, and be prepared to discuss these in the context of their goals of care and potential impact on quality of life. Respect for our patients’ autonomy is critical when discussing these issues, but we should always be guided by the ethical principles of beneficence and non-maleficence.

UR - http://www.scopus.com/inward/record.url?scp=85040981986&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040981986&partnerID=8YFLogxK

U2 - 10.1080/21678421.2018.1425455

DO - 10.1080/21678421.2018.1425455

M3 - Article

VL - 19

SP - 167

EP - 172

JO - Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

JF - Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

SN - 2167-8421

IS - 3-4

ER -